Navigation Links
Drug for Cancer to be on Pharmaceutical Benefits Scheme

The Federal Government and drug company, Roche are conducting talks to make the expensive anti-cancer treatment, Herceptin more widely available.//

According to Health Minister Tony Abbott discussions with manufacturer Roche has caused the delay in rushing Herceptin on to the Pharmaceutical Benefits Scheme (PBS).

Mr Abbott said,'It is important the Government try to get the best possible deal for taxpayers as well as the best possible deal for patients. So we are to some extent at least dependent on discussions with Roche, the company which makes the drug.'

Mortality rate caused by some types of breast cancer appears to be reduced with Herceptin. However the drug, which costs $50,000 to $60,000 per patient each year, is far too expensive for some victims.

The Government would have to spend about $100 million per year by listing Herceptin on the PBS but it would serve to make this drug more widely available.

According to Mr Abbot the listing of Herceptin was moving ahead more quickly than any other drug since he had become Health Minister.

He said, 'The Government has been pursuing this as quickly as possible. We expedited the consideration of Herceptin by the Therapeutic Goods Administration. We expedited the consideration by the Pharmaceutical Benefits Advisory Committee, and it will now get expedited consideration by Cabinet.'

The drug's benefits lie in reducing the chance of cancer reoccurring in women with a particular type of early-stage breast cancer.

If the Government accepts the recommendation of the Pharmaceutical Benefits Advisory Committee, the drug would be available to around 2100 patients for a subsidized price rather than the current cost.


'"/>




Page: 1

Related medicine news :

1. Fibroids unlikely to Turn Cancerous
2. Virus Level could Predict Cervical Cancer Risk
3. Cancer Doctors Okays Controversial Prostate Therapy
4. Potential New Cancer Gene Identified
5. Consensus on "Combination Therapy" for Breast Cancer
6. Cancers of Colon & Rectum linked to Cigarette Smoking
7. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
8. The Cancer Rumour mill working over time
9. Cancer drugs in development nearly doubled since 1995
10. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
11. Cancer patients turning to Internet for information
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal ... program today with a new Indiegogo campaign . Individuals are now able ... in the Los Angeles area, either as a participating patient or through an Indiegogo ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for ... expert sit stand solutions representative to the Minneapolis Home and Garden Show which is ... event that is garnering national attention is the Minneapolis Convention Center. , From ...
(Date:2/23/2017)... ... February 23, 2017 , ... Carlos Gutierrez ... has also continued to spiritually evolve, which is the purpose of everyone in this ... Spiritual Truths ” (published by Balboa Press) attempts to guide readers to expand one’s ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... athletics. It’s enough to overwork even the sharpest brain. , Power On, a ... healthy activity without over clocking the brain. Each capsule contains Cognizin® Citicoline, a ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... medicine in recent years. The technology is so cutting edge, in fact, the ... protocol for stem cell procedures. However, successful patient outcomes in certain clinical stem ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... DUBLIN , Feb 23, 2017 Research ... Prosthetic Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 9.2% over the next ... industry report analyzes the market estimates and forecasts for all the ...
(Date:2/23/2017)... 23, 2017 MabVax Therapeutics Holdings, ... development company, announces that it has received notice ... authorizing the initiation a Phase I clinical trial ... cancer. MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s ... to initiate the phase I clinical trial in ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: